AR034119A1 - Compuestos de 5-alquilpirido pirimidinas, composicion farmaceutica, uso para prepararla y metodo para inhibir cinasas con dichos compuestos - Google Patents
Compuestos de 5-alquilpirido pirimidinas, composicion farmaceutica, uso para prepararla y metodo para inhibir cinasas con dichos compuestosInfo
- Publication number
- AR034119A1 AR034119A1 ARP010101039A ARP010101039A AR034119A1 AR 034119 A1 AR034119 A1 AR 034119A1 AR P010101039 A ARP010101039 A AR P010101039A AR P010101039 A ARP010101039 A AR P010101039A AR 034119 A1 AR034119 A1 AR 034119A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently selected
- lower alkyl
- halogen
- trifluoromethyl
- carbocyclic group
- Prior art date
Links
- -1 PYRIMIDINES COMPOUNDS Chemical class 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 11
- 125000002837 carbocyclic group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 229910052717 sulfur Inorganic materials 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 6
- 229910052757 nitrogen Chemical group 0.000 abstract 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 5
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 239000001301 oxygen Substances 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 239000011593 sulfur Chemical group 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 150000002825 nitriles Chemical class 0.000 abstract 4
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 abstract 3
- 229960001171 acetohydroxamic acid Drugs 0.000 abstract 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 3
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 101100295741 Gallus gallus COR4 gene Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos de fórmula (1) donde: R2 es (a) hidrógeno; (b) alquilo inferior, sustituido, en forma opcional por 1, 2, ó 3 grupos seleccionados en forma independiente de: halógeno, hidroxi, alcoxi inferior, amino, mono- o dialquilamino, carboxi, alcoxicarbonilo, tioalquilo, nitrilo, arilo, heteroarilo, o un grupo carbocíclico que contiene de 3 a 7 elementos, hasta dos de cuyos elementos son en forma opcional heteroátomos seleccionados en forma independiente de oxígeno, azufre, y nitrógeno; o (c) un grupo carbocíclico que contiene de 3 a 7 elementos, hasta dos de cuyos elementos son en forma opcional heteroátomos seleccionados en forma independiente de oxígeno, azufre, y nitrógeno, donde el grupo carbocíclico es insustituido o sustituido con 1, 2 ó 3 grupos seleccionados, en forma independiente, de halógeno, hidroxi, alquilo inferior, alcoxi inferior, amino, mono- o dialquilamino, arilo, y heteroarilo; R3 es hidrógeno, alquilo inferior, alcoxi inferior, halógeno, trifluorometilo, alquinilo inferior, alquenilo inferior, nitrilo, nitro, -COR4, -CO2R4, -CONR4R5, -CONR4OR5, -SO2NR4R5, -SO2R4, -SO3R4, P(O)(OR4)(OR5), o -NR4R5; Y es N ó CR7; R9 es alquilo inferior, haloalquilo, o arilo; X y Z son, en forma independiente hidrógeno, halógeno, alquilo inferior, alcoxi inferior, trifluorometilo, hidroxi, nitrilo, nitro, -NR4R5, -N(O)R4R5, -NR4R5R6W, -SR4, -C(O)R4, -CO2R4, -CONR4R5, -SO2NR4R5, -SO2R4, -SO3R4, P(O)(OR4)(OR5), -T(CH2)mQR4, -C(O)T(CH2)mQR4, o -NR4C(O)T(CH2)mQR5; m es 1-6; T es O, S, NR4, N(O)R4, NR4R5W, o CR4R5; Q es O, S, NR4, N(O)R4, NR4R5W, CO2, o un grupo carbocíclico que contiene de 3 a 7 elementos, hasta cuatro de cuyos elementos son, en forma opcional heteroátomos seleccionados en forma independiente de oxígeno, azufre, y nitrógeno, donde el grupo carbocíclico es insustituido o sustituido con 1, 2 ó 3 grupos seleccionados en forma independiente de halógeno, hidroxi, hidroxialquilo, alquilo inferior, alcoxi inferior, alcoxicarbonilo, alquilcarbonilo, alquilcarbonilamino, aminoalquilo, trifluorometilo, N-hidroxiacetamida, trifluorometilalquilo, amino, o mono o dialquilamino; R6 es alquilo inferior, haloalquilo, o arilo; R7 es NR4R5, N(O)R4R5, NR4R5R9W, OH, OR4, SR4, halo, COR4, (CH2)nR4, CO2R4, CONR4R5, C(O)NR4SO2R5, S(O)R4, SO2R4, SO2NR4R5, SO3R4, (CH2)nP(O)(OR4)2, NR4SO2R5, aldehído, nitrilo, nitro, alquilo, alcoxialquilo, T(CH2)mQR4, C(O)T(CH2)mQR4, NR4C(O)T(CH2)mQR5, o T(CH2)mCO2R4; n es 0-6; W es un anión; R4 y R5 son en forma independiente hidrógeno, alquilo inferior, alquenilo inferior, alquinilo inferior, (CH2)nAr, arilalquilo, arilo, heteroarilo, heteroarilalquilo, cicloalquilo, o heterocicloalquilo, o R4 y R5 junto con el nitrógeno al cual están unidos forman un anillo carbocíclico que contiene de 3 a 8 elementos, hasta cuatro de cuyos elementos son, en forma opcional, grupos carbonilo o heteroátomos seleccionados, en forma independiente, de oxígeno, azufre, S(O), S(O)2, y nitrógeno, donde el grupo carbocíclico es insustituido o sustituido con 1, 2, 3 ó 4 grupos seleccionados, en forma independiente, de halógeno, hidroxi, hidroxialquilo, alquilo inferior, alcoxi inferior, alcoxicarbonilo, alquilcarbonilo, alquilcarbonilamino, aminoalquilo, aminoalquilcarbonilo, trifluorometilo, trifluorometilalquilo, trifluorometilalquilaminoalquilo, amino, mono- o dialquilamino, N-hidroxiacetamido, arilo, heteroarilo, carboxialquilo, NR10SO2R11, C(O)NR10R11, NR10C(O)R11, C(O)OR10, C(O)NR10SO2R11, (CH2)nS(O)nR10, (CH2)n-heteroarilo, O(CH2)n-heteroarilo, (CH2)nC(O)NR10R11, O(CH2)nC(O)OR10; y R4, en forma adicional, puede ser alquilo inferior insustituido o sustituido con 1, 2, ó 3 grupos seleccionados, en forma independiente, de halógeno, 5-oxo-4,5-dihidro-1H-1,2,4-triazol-3-il-sulfanil, 5-oxo-4,5-dihidro-1H-1,2,4-triazol-3-il-sulfinil, 5-oxo-4,5-dihidro-1H-1,2,4-triazol-3-il-sulfonil, o un grupo carbocíclico que contiene de 3 a 7 elementos, hasta cuatro de cuyos elementos son, en forma opcional, heteroátomos seleccionados en forma independiente de oxígeno, azufre y nitrógeno, donde el grupo carbocíclico es insustituido o sustituido con 1, 2, ó 3 grupos seleccionados en forma independiente de halógeno, hidroxi, hidroxialquilo, alquilo inferior, alcoxi inferior, alcoxicarbonilo, alquilcarbonilo, alquilcarbonilamino, aminoalquilo, trifluorometilo, N-hidroxiacetamida, trifluorometilalquilo, amino, o mono- o dialquilamino; y R10 y R11 son, en forma independiente, hidrógeno, halógeno, alquilo inferior, alcoxi inferior, o alquilcarbonilo; y sus sales, ésteres, amidas y prodrogas aceptables para uso farmacéutico. Composición farmacéutica que los comprende y uso para preparar dicha composición, que es útil para el tratamiento de trastornos proliferativos. Método para inhibir cinasas con dichos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18712400P | 2000-03-06 | 2000-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034119A1 true AR034119A1 (es) | 2004-02-04 |
Family
ID=22687699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101039A AR034119A1 (es) | 2000-03-06 | 2001-03-05 | Compuestos de 5-alquilpirido pirimidinas, composicion farmaceutica, uso para prepararla y metodo para inhibir cinasas con dichos compuestos |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP1268476A1 (es) |
| JP (1) | JP2003528101A (es) |
| KR (1) | KR20020075805A (es) |
| CN (1) | CN1422268A (es) |
| AP (1) | AP2002002643A0 (es) |
| AR (1) | AR034119A1 (es) |
| AU (1) | AU2001233028A1 (es) |
| BG (1) | BG107161A (es) |
| BR (1) | BR0109056A (es) |
| CA (1) | CA2401368A1 (es) |
| CO (1) | CO5280200A1 (es) |
| CR (1) | CR6736A (es) |
| CZ (1) | CZ20022929A3 (es) |
| DZ (1) | DZ3308A1 (es) |
| EA (1) | EA200200802A1 (es) |
| EE (1) | EE200200506A (es) |
| GT (1) | GT200100037A (es) |
| HN (1) | HN2001000040A (es) |
| HR (1) | HRP20020798A2 (es) |
| HU (1) | HUP0300136A2 (es) |
| IL (1) | IL151480A0 (es) |
| IS (1) | IS6524A (es) |
| MA (1) | MA26881A1 (es) |
| MX (1) | MXPA02008535A (es) |
| NO (1) | NO20024235L (es) |
| NZ (1) | NZ520962A (es) |
| OA (1) | OA12227A (es) |
| PA (1) | PA8513201A1 (es) |
| PE (1) | PE20011177A1 (es) |
| PL (1) | PL358271A1 (es) |
| SK (1) | SK12472002A3 (es) |
| SV (1) | SV2001000338A (es) |
| TN (1) | TNSN01036A1 (es) |
| WO (1) | WO2001070741A1 (es) |
| YU (1) | YU66502A (es) |
| ZA (1) | ZA200207110B (es) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053070B2 (en) * | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| WO2002059083A2 (en) | 2000-10-23 | 2002-08-01 | Smithkline Beecham Corporation | Novel compounds |
| DE60206363T2 (de) * | 2001-02-12 | 2006-07-06 | F. Hoffmann-La Roche Ag | 6-substituierte pyridopyrimidine |
| CA2438294C (en) | 2001-02-26 | 2008-10-21 | Tanabe Seiyaku Co., Ltd. | Pyridopyrimidine or naphthyridine derivative |
| WO2003000270A1 (en) * | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel pyridopyrimidones and uses thereof |
| AU2002324450A1 (en) * | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel pyridopyrimidines and uses thereof |
| GEP20063909B (en) | 2002-01-22 | 2006-08-25 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES |
| JP4603268B2 (ja) | 2002-04-19 | 2010-12-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規化合物 |
| US7585866B2 (en) | 2002-07-31 | 2009-09-08 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
| WO2004033446A1 (en) | 2002-10-09 | 2004-04-22 | Danter Wayne R | Protein tyrosine kinase inhibitors |
| ATE433967T1 (de) * | 2003-01-17 | 2009-07-15 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| NZ544609A (en) * | 2003-07-11 | 2008-07-31 | Warner Lambert Co | Isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one |
| JP5010917B2 (ja) * | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| EP1685131B1 (en) | 2003-11-13 | 2007-03-07 | F. Hoffmann-La Roche AG | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| FR2873118B1 (fr) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| EP1630163A1 (de) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| JP2008510770A (ja) * | 2004-08-26 | 2008-04-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｌｋ阻害剤としての新規プテリジノン |
| DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| CA2594860A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
| PE20100737A1 (es) | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | Nuevos compuestos |
| SG160438A1 (en) | 2005-03-25 | 2010-04-29 | Glaxo Group Ltd | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5- d]pyrimidin-2(1h)-one derivatives |
| US20090137550A1 (en) | 2005-03-25 | 2009-05-28 | Glaxo Group Limited | Novel Compounds |
| UY29439A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| US7737155B2 (en) * | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| FR2887882B1 (fr) | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique |
| TW200800983A (en) | 2005-09-14 | 2008-01-01 | Janssen Pharmaceutica Nv | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase |
| US7642270B2 (en) | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
| WO2007044813A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
| JP5480503B2 (ja) * | 2005-10-07 | 2014-04-23 | エクセリクシス， インク． | ＰＩ３Ｋαのピリドピリミジノン型阻害剤 |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| PL2074122T3 (pl) | 2006-09-15 | 2011-10-31 | Pfizer Prod Inc | Związki pirydo(2,3-D)pirymidynonowe i ich zastosowanie jako inhibitory PI3 |
| JP2010506902A (ja) * | 2006-10-16 | 2010-03-04 | ジーピーシー・バイオテック・インコーポレーテッド | ピリド［２，３−ｄ］ピリミジン類およびキナーゼ阻害剤としてのそれらの使用 |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| WO2008055013A2 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase |
| FR2910813B1 (fr) | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | Nouvelle utilisation therapeutique pour le traitement des leucemies |
| US8138181B2 (en) * | 2007-04-03 | 2012-03-20 | Array Biopharma Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
| SI2168966T1 (sl) | 2007-06-15 | 2017-03-31 | Msd K.K. | Derivat biciklo anilina |
| EP3098223A1 (en) | 2007-08-03 | 2016-11-30 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
| AU2008343932B2 (en) | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| US8466151B2 (en) | 2007-12-26 | 2013-06-18 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| EP2100894A1 (en) * | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| ATE531372T1 (de) * | 2008-04-07 | 2011-11-15 | Amgen Inc | Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| UY32153A (es) | 2008-09-30 | 2011-04-29 | Exelixis Inc | Inhibidores de piridomidinona de pi13ka(alfa) y mtor |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| MX2012004157A (es) * | 2009-10-09 | 2012-08-03 | Afraxis Inc | 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc. |
| WO2011075616A1 (en) | 2009-12-18 | 2011-06-23 | Temple University - Of The Commonwealth System Of Higher Education | Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof |
| AR080151A1 (es) | 2010-02-09 | 2012-03-14 | Exelixis Inc | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia |
| US8987272B2 (en) | 2010-04-01 | 2015-03-24 | Critical Outcome Technologies Inc. | Compounds and method for treatment of HIV |
| US8987267B2 (en) | 2010-08-05 | 2015-03-24 | Temple University—Of the Commonwealth System of Higher Education | 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| PT2646448T (pt) | 2010-11-29 | 2017-10-04 | Osi Pharmaceuticals Llc | Inibidores macrocíclicos de cinases |
| WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| KR102027598B1 (ko) * | 2011-05-17 | 2019-10-01 | 프린시피아 바이오파마, 인코퍼레이티드 | 타이로신 키나아제 저해제 |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| EP2817308B1 (en) * | 2012-02-23 | 2016-09-07 | AbbVie Inc. | Pyridopyrimidinone inhibitors of kinases |
| EP2958916B1 (en) * | 2013-02-21 | 2018-09-12 | Pfizer Inc | Solid forms of a selective cdk4/6 inhibitor |
| JP2016525532A (ja) | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 骨髄異形成症候群の処置 |
| JP6631616B2 (ja) * | 2014-07-26 | 2020-01-15 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用 |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| TWI646094B (zh) * | 2016-06-01 | 2019-01-01 | 大陸商貝達藥業股份有限公司 | Crystal form of inhibitory protein kinase active compound and application thereof |
| PE20190475A1 (es) | 2016-08-15 | 2019-04-04 | Pfizer | Inhibidores de cdk2/4/6 |
| US11192890B2 (en) * | 2017-03-03 | 2021-12-07 | Auckland Uniservices Limited | FGFR kinase inhibitors and pharmaceutical uses |
| EP3752491A4 (en) | 2018-02-15 | 2021-12-01 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS |
| CN113166148B (zh) * | 2018-12-07 | 2024-04-12 | 杭州英创医药科技有限公司 | 作为cdk-hdac双通路抑制剂的杂环化合物 |
| CN112759589B (zh) * | 2019-11-01 | 2022-04-08 | 暨南大学 | 嘧啶并吡啶酮类化合物及其应用 |
| EP4065578A1 (en) | 2019-11-26 | 2022-10-05 | Theravance Biopharma R&D IP, LLC | Fused pyrimidine pyridinone compounds as jak inhibitors |
| WO2022188755A1 (zh) * | 2021-03-08 | 2022-09-15 | 暨南大学 | 吡啶并嘧啶类化合物及其应用 |
| KR20240021239A (ko) * | 2021-06-09 | 2024-02-16 | 티와이케이 메디슨즈, 인코포레이티드 | Cdk 키나아제 억제제로 사용되는 화합물 및 이의 용도 |
| JP2025531320A (ja) * | 2022-09-16 | 2025-09-19 | イースト チャイナ ノーマル ユニバーシティ | Ｒｓｋ阻害剤としてのピリドノピリミジン誘導体及びその応用 |
| WO2024099403A1 (zh) * | 2022-11-10 | 2024-05-16 | 北京普祺医药科技股份有限公司 | 一种具有软药性质的硫醚类化合物、药物组合物及其用途 |
| WO2024107730A1 (en) * | 2022-11-14 | 2024-05-23 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| BR9807305A (pt) * | 1997-02-05 | 2000-05-02 | Warner Lambert Co | Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular. |
| KR20010043829A (ko) * | 1998-05-26 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘 |
-
2001
- 2001-01-29 YU YU66502A patent/YU66502A/sh unknown
- 2001-01-29 IL IL15148001A patent/IL151480A0/xx unknown
- 2001-01-29 EE EEP200200506A patent/EE200200506A/xx unknown
- 2001-01-29 PL PL01358271A patent/PL358271A1/xx not_active Application Discontinuation
- 2001-01-29 SK SK1247-2002A patent/SK12472002A3/sk unknown
- 2001-01-29 BR BR0109056-9A patent/BR0109056A/pt not_active IP Right Cessation
- 2001-01-29 EA EA200200802A patent/EA200200802A1/ru unknown
- 2001-01-29 NZ NZ520962A patent/NZ520962A/en unknown
- 2001-01-29 JP JP2001568942A patent/JP2003528101A/ja not_active Abandoned
- 2001-01-29 HU HU0300136A patent/HUP0300136A2/hu unknown
- 2001-01-29 WO PCT/US2001/002657 patent/WO2001070741A1/en not_active Ceased
- 2001-01-29 CA CA002401368A patent/CA2401368A1/en not_active Abandoned
- 2001-01-29 MX MXPA02008535A patent/MXPA02008535A/es not_active Application Discontinuation
- 2001-01-29 CZ CZ20022929A patent/CZ20022929A3/cs unknown
- 2001-01-29 OA OA1200200281A patent/OA12227A/en unknown
- 2001-01-29 CN CN01807590A patent/CN1422268A/zh active Pending
- 2001-01-29 AP APAP/P/2002/002643A patent/AP2002002643A0/en unknown
- 2001-01-29 HR HR20020798A patent/HRP20020798A2/xx not_active Application Discontinuation
- 2001-01-29 AU AU2001233028A patent/AU2001233028A1/en not_active Abandoned
- 2001-01-29 KR KR1020027011627A patent/KR20020075805A/ko not_active Withdrawn
- 2001-01-29 DZ DZ013308A patent/DZ3308A1/fr active
- 2001-01-29 EP EP01905114A patent/EP1268476A1/en not_active Withdrawn
- 2001-03-02 TN TNTNSN01036A patent/TNSN01036A1/en unknown
- 2001-03-05 SV SV2001000338A patent/SV2001000338A/es not_active Application Discontinuation
- 2001-03-05 HN HN2001000040A patent/HN2001000040A/es unknown
- 2001-03-05 CO CO01017398A patent/CO5280200A1/es not_active Application Discontinuation
- 2001-03-05 AR ARP010101039A patent/AR034119A1/es unknown
- 2001-03-05 PA PA20018513201A patent/PA8513201A1/es unknown
- 2001-03-05 PE PE2001000216A patent/PE20011177A1/es not_active Application Discontinuation
- 2001-03-05 GT GT200100037A patent/GT200100037A/es unknown
-
2002
- 2002-08-23 CR CR6736A patent/CR6736A/es not_active Application Discontinuation
- 2002-08-23 IS IS6524A patent/IS6524A/is unknown
- 2002-09-04 MA MA26801A patent/MA26881A1/fr unknown
- 2002-09-04 ZA ZA200207110A patent/ZA200207110B/en unknown
- 2002-09-05 NO NO20024235A patent/NO20024235L/no not_active Application Discontinuation
- 2002-10-02 BG BG107161A patent/BG107161A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034119A1 (es) | Compuestos de 5-alquilpirido pirimidinas, composicion farmaceutica, uso para prepararla y metodo para inhibir cinasas con dichos compuestos | |
| AR022283A1 (es) | Aminas substituidas de espirofuropiridinas novedosas utiles en terapia | |
| AR060316A1 (es) | Azaindoles de utilidad como inhibidores de janus quinasas | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| AR038814A1 (es) | Compuestos de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-ona y uso en la fabricacion de medicamentos | |
| UY28149A1 (es) | Compuestos quimicos | |
| AR040700A1 (es) | Derivados de pirimidilsulfonamida como moduladores de receptores de quimioquinas | |
| AR011170A1 (es) | Atropoisomeros de 2-(aril o heteroaril)-3-aril-4 (3h)-quinazolinonas y composiciones farmaceuticas que los contienen | |
| AR046792A1 (es) | Fenilalanina-amidas sustituidas por heteroaroilo, un procedimiento para su preparacion, utilizacion de las mismas como herbicidas y productos fitosa-nitarios que los contienen como principio activo | |
| AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
| ECSP088246A (es) | Nuevos derivados de benzotiazolona | |
| RU2018112252A (ru) | Конденсированное пиримидиновое соединение или его соль | |
| CA2044748A1 (en) | Pyrazolopyrimidinone antianginal agents | |
| UY30681A1 (es) | Compuestos de piridinamida que contienen carboxi, sales farmacéuticamente aceptables, procedimientos para la preparacion de los mismos, composiciones que los contienen y sus usos. | |
| NO983687D0 (no) | Kinazolin-derivater som VEGF-inhibitorer | |
| CO5560575A2 (es) | Compuestos derivados de dihidro-pteridinonas caracterizados por ser inhibidores de especificas cinasas del ciclo celular y preparaciones farmaceuticas que los contienen | |
| HRP20120963T1 (hr) | PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI | |
| AR046118A1 (es) | Procedimiento para la preparacion de compuestos de aminocrotonilo | |
| AR065813A1 (es) | Compuesto composicion farmaceutica y metodos para tratar trastornos relacionados con pi3k y mtor y a cancer y para inhibir mtor y pi3k | |
| AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
| ECSP099335A (es) | Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos | |
| ITRM20010465A1 (it) | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
| AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |